Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune Inc.
Replimune Inc.
Myeloid Therapeutics
Bolt Biotherapeutics, Inc.
Compugen Ltd
Eli Lilly and Company
Astellas Pharma Inc
OHSU Knight Cancer Institute
Fondazione per la Medicina Personalizzata
Fate Therapeutics
Fate Therapeutics
Jules Bordet Institute
Celgene